Tislelizumab
- Generic Name
- Tislelizumab
- Brand Names
- Tevimbra, Tizveni
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1858168-59-8
- Unique Ingredient Identifier
- 0KVO411B3N
- Background
Tislelizumab is under investigation in clinical trial NCT02660034 (The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Subjects With Advanced Solid Tumors).
- Indication
⑴用于治疗至少经过二线系统化疗的复发或难治性经典型霍奇金淋巴瘤（R/R cHL）患者。
⑵用于治疗局部晚期或转移性尿路上皮癌。
⑶联合化疗用于治疗一线晚期非鳞状非小细胞肺癌（NSCLC）患者。
⑷用于治疗既往接受过治疗的不可切除肝细胞癌患者。
⑸用于治疗晚期恶性实体瘤
- Associated Conditions
- -
- Associated Therapies
- -
HAIC+Lenvatinib+Tislelizumab vs D-TACE+Lenvatinib+Tislelizumab for Unresectable HCC
- Conditions
- Interventions
- First Posted Date
- 2022-10-17
- Last Posted Date
- 2022-10-17
- Lead Sponsor
- Wen Li
- Target Recruit Count
- 60
- Registration Number
- NCT05582278
- Locations
- 🇨🇳
The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
A Phase 1/2a Study Evaluating Allocetra-OTS as Monotherapy or in Combination With Anti-PD-1 Therapy for the Treatment of Advanced Solid Tumor Malignancy
- Conditions
- Interventions
- First Posted Date
- 2022-10-14
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Enlivex Therapeutics RDO Ltd.
- Target Recruit Count
- 14
- Registration Number
- NCT05581719
- Locations
- 🇮🇱
Hadassah Medical Center, Jerusalem, Israel
🇮🇱Sourasky Medical Center, Tel Aviv, Israel
🇪🇸Clínica Universidad de Navarra, Madrid, Spain
Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-10-13
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 121
- Registration Number
- NCT05577702
- Locations
- 🇨🇳
Hwa Mei Hospital, University of Chinese Academy of Sciences (Ningbo No Hospital), Ningbo, Zhejiang, China
🇨🇳The First Affiliated Hospital of Wannan Medical College, Wuhu, Anhui, China
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China
Efficacy and Safety of Sitravatinib Plus Tislelizumab or Placebo Plus Tislelizumab Versus Placebo as Adjuvant Treatment in Participants With Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2022-10-03
- Last Posted Date
- 2023-06-07
- Lead Sponsor
- BeiGene
- Registration Number
- NCT05564338
Sitravatinib and Tislelizumab in Patients With Metastatic Uveal Melanoma With Liver Metastases.
- Conditions
- Interventions
- First Posted Date
- 2022-09-15
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- Grupo Español Multidisciplinar de Melanoma
- Target Recruit Count
- 16
- Registration Number
- NCT05542342
- Locations
- 🇪🇸
Hospital Universitario Virgen de la Macarena, Sevilla, Andalucia, Spain
🇪🇸Hospital General Universitario de Valencia, Valencia, Spain
🇪🇸Hospital Universitario la Paz, Madrid, Spain
The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy)
- Conditions
- Interventions
- First Posted Date
- 2022-09-10
- Last Posted Date
- 2023-03-09
- Target Recruit Count
- 38
- Registration Number
- NCT05536102
- Locations
- 🇨🇳
Shanghai General Hospital, Shanghai, China
Nocardia Rubra Cell Wall Skeleton (N-CWS) Plus HAIC, Lenvatinib and Tislelizumab in Treating Patients With Advanced HCC
- Conditions
- Interventions
- First Posted Date
- 2022-09-09
- Last Posted Date
- 2023-12-19
- Lead Sponsor
- Wan-Guang Zhang
- Target Recruit Count
- 30
- Registration Number
- NCT05533892
- Locations
- 🇨🇳
Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Risk-stratification Based Bladder-sparing Modalities for Muscle-invasive Bladder Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-09-07
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 30
- Registration Number
- NCT05531123
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
A Single-arm Exploratory Study of Neoadjuvant Therapy
- Conditions
- Interventions
- First Posted Date
- 2022-09-06
- Last Posted Date
- 2023-06-08
- Lead Sponsor
- Jun Liu
- Target Recruit Count
- 28
- Registration Number
- NCT05527808
- Locations
- 🇨🇳
First Affiliated Hospital, Guangzhou Medical University, Guangzhou, Please Select, China
Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer
- First Posted Date
- 2022-09-02
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 30
- Registration Number
- NCT05526924
- Locations
- 🇺🇸
The University of Chicago, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.